RE:RE:RE: 1 share tradedIn our call last week, the confidence level was pretty high. I would be surprised if they did not have something to report from phase 1a besides MTD that will eventually move the market higher. Their strategy appears to be to hide that info from us for a few weeks and share it with the eggheads at that conference in late June first (what is the name of that conference again?) but that is not surprising as it is the way things are done in the biotech world. Maybe we will get lucky and people will start to be interested in biotechs again by then. They may also get one of the coveted late-breaker sessions - that will be something to look out for in the otherwise likely bland release of the phase 1a MTD although I don't know how far ahead of the meeting such things are announced.
On strategy, they are clearly following the IMMU model for now although I am sure that could change over time. On the phase 1b, they are adding five sites in the US and 6 in Europe,most likely in July since getting Europe up and runing takes more time. Paul's emphasis was to do things correctly in setting up the phase 1b, which I took as an indication they have something interesting in the phase 1a data and don't want to do anything to mess it up.
A potential negative side-effect if they do a debt financing - there is less immediate interest on achieving a legitmate price for the stock. But I am really not sure what they are planning on the financing front. I would not be surprised if we got a MDGL-like PR at some point soon where great confidence is expressed on TH-1902 and a debt deal like the one MDGL arranged is announced (MDGL's debt deal was for $250 million of which MDGL drew down $50 million immediately). A smaller version fo that would make sense for TH.
Wino115 wrote: ..and the wide spread of 10cents shows there is a high degree of uncertainty so both seller and buyer need to be enticed at either end instead of a liquid market with a lot of depth creating a very tight spread so you can transact. It's all about lack of information with a dwindling and very small audience. Once again, the upside to it would be IF there is positive info, it will work the opposite way. Maybe they can attract an audience, transactions go up, spreads diminish, share rises. But they need something positive first.
Seems we'll get dosage, safety info in brief form, a possible conferece poster later, and a larger push in to the basket trial. But they should at a minimum lay out to the investors what the plan now looks like, what the regulatory strategy is, the PPD/Clinic recruiting strategy is, etc... There's just still so much they could educate the market about but sounds like they could care less about doing so if they just release "We hit MTD and will use 300mg as RP2D. No SAEs there. On to basket trial. More later." That would be a bigtime mistake. Start building the audience now. Forget about saving things for a conference to win personal accolades. We're talking the fair valuation of your company here, not scoring points in the oncology egghead world.
SPCEO1 wrote: Sad and incomprehensible.
SS1316 wrote: I'm showing That as of 10:12 am EST only 1 share has been traded... sad